Abstract: A method of delivering an active ingredient to a subject in need thereof is provided. The method includes administering to the subject a therapeutically effective amount of a formulation comprising biodegradable, polymeric microparticles and an active ingredient selected from the group consisting of levo-alpha-acetylmethadol (LAAM), nor-LAAM, and dinor-LAAM, wherein the active ingredient is part of a hydrophobic ion-pairing (HIP) complex and wherein the HIP complex is associated with the microparticles. Sustained release formulations containing an active ingredient are also provided.

Abstract: Pharmaceutical particles having an inner portion comprising an agonist of peroxisome proliferator-activated receptor ? (PPAR?) and a biodegradable polymer; and an outer coating comprising an emulsifier which surrounds the inner portion, wherein the agonist may be a fibrate, and the particle contains at least about 5 wt % to about 25 wt % of the agonist, and wherein the particle has a sustained delayed release of the agonist in a range of at least about 1 to 12 months when in an aqueous solution or physiological environment. The pharmaceutical particles may be used, for example, to treat diseases and conditions such as ocular disorders which benefit from PPAR? agonism.

Abstract: Pharmaceutical particles having an inner portion comprising an agonist of peroxisome proliferator-activated receptor ? (PPAR?) and a biodegradable polymer; and an outer coating comprising an emulsifier which surrounds the inner portion, wherein the agonist may be a fibrate, and the particle contains at least about 5 wt % to about 25 wt % of the agonist, and wherein the particle has a sustained delayed release of the agonist in a range of at least about 1 to 12 months when in an aqueous solution or physiological environment. The pharmaceutical particles may be used, for example, to treat diseases and conditions such as ocular disorders which benefit from PPAR? agonist.